tirzepatide heart and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Failure Management - Abdul‐Hafez - 2026 - Endocrinology, Diabetes & Metabolism Tirzepatide Reduces Heart Failure Risk,

Medically supervised weight loss involves more than simply administering injections

Both of these peptides are rapidly degraded by the enzyme DPP-4, which is expressed in a number of sites, including the endothelial cells of small gut arterioles

doi: 10.1210/mend-3-6-1014

Mounjaro (tirzepatide) injection, for subcutaneous use, Food and Drug Administration (2026) FDA approves Lillys Mounjaro (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with Type 2 diabetes, Eli Lilly (2022) Mounjaro (tirzepatide) Injection: The first and only GIP and GLP-1 receptor agonist approved for Type 2 Diabetes, Eli Lilly Declaratory order: Resolution of shortages of tirzepatide injection products (Mounjaro and Zepbound), Food and Drug Administration (2024) FDAs concerns with unapproved GLP-1 drugs used for weight loss, Food and Drug Administration (2024) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice

They can provide guidance and adjust your treatment plan as needed